全文获取类型
收费全文 | 34126篇 |
免费 | 2746篇 |
国内免费 | 417篇 |
专业分类
耳鼻咽喉 | 359篇 |
儿科学 | 1010篇 |
妇产科学 | 608篇 |
基础医学 | 4947篇 |
口腔科学 | 517篇 |
临床医学 | 3211篇 |
内科学 | 7348篇 |
皮肤病学 | 760篇 |
神经病学 | 2584篇 |
特种医学 | 1289篇 |
外国民族医学 | 16篇 |
外科学 | 4177篇 |
综合类 | 1280篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 2672篇 |
眼科学 | 680篇 |
药学 | 2575篇 |
6篇 | |
中国医学 | 622篇 |
肿瘤学 | 2625篇 |
出版年
2023年 | 269篇 |
2022年 | 646篇 |
2021年 | 1081篇 |
2020年 | 673篇 |
2019年 | 839篇 |
2018年 | 1037篇 |
2017年 | 751篇 |
2016年 | 744篇 |
2015年 | 905篇 |
2014年 | 1155篇 |
2013年 | 1503篇 |
2012年 | 2178篇 |
2011年 | 2187篇 |
2010年 | 1350篇 |
2009年 | 1119篇 |
2008年 | 1612篇 |
2007年 | 1657篇 |
2006年 | 1585篇 |
2005年 | 1490篇 |
2004年 | 1327篇 |
2003年 | 1266篇 |
2002年 | 1198篇 |
2001年 | 1112篇 |
2000年 | 1100篇 |
1999年 | 977篇 |
1998年 | 343篇 |
1997年 | 299篇 |
1996年 | 262篇 |
1995年 | 211篇 |
1994年 | 208篇 |
1993年 | 174篇 |
1992年 | 516篇 |
1991年 | 499篇 |
1990年 | 474篇 |
1989年 | 432篇 |
1988年 | 452篇 |
1987年 | 381篇 |
1986年 | 372篇 |
1985年 | 365篇 |
1984年 | 255篇 |
1983年 | 187篇 |
1982年 | 119篇 |
1981年 | 103篇 |
1979年 | 210篇 |
1978年 | 111篇 |
1977年 | 124篇 |
1976年 | 113篇 |
1974年 | 130篇 |
1972年 | 128篇 |
1969年 | 104篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
目的 探讨肝动脉介入栓塞术治疗肝血管瘤患者的疗效及血清甘氨酰脯氨酸二肽氨基肽酶(GPDA)、高尔基体蛋白73(GP73)和β2-微球蛋白(β2-MG)水平的变化。方法 2017年1月~2019年1月我院肝病科收治的60例肝血管瘤患者被随机分为介入手术组30例和开腹肝切除术组30例,分别接受经肝动脉介入栓塞术或开腹肝切除术。术后,随访半年。采用ELISA法检测血清GPDA、GP73、β2-MG水平及肿瘤坏死因子-α(TNF-α)、肿瘤特异性生长因子(TSGF)和甲胎蛋白(AFP)水平。结果 介入手术组手术时间和术后住院时间分别为(84.7±21.9) min和(6.7±1.3)d,均显著短于开腹肝切除术组【分别为(126.8±60.5)min和(9.6±5.8)d,P<0.05】,术中出血量为(110.7±13.5)mL,显著少于开腹肝切除术组【(315.5±17.8)mL,P<0.05】;在术后1 w,介入手术组血清GPDA、GP73、β2-MG、TNF-α、TSGF和AFP水平分别为(62.6±9.8)U/L、(64.3±6.7)μg/L、(1.4±0.5)mg/L、(1.3±0.5)mg/L、(35.5±4.3)U/mL和(2.5±0.6)mg/L,均显著低于开腹肝切除术组【分别为(86.4±11.5)U/L、(112.2±9.3)μg/L,(2.3±0.9)mg/L,(2.1±1.2)mg/L,(61.3±9.8)U/mL和(4.7±0.8)mg/L,P<0.05】;介入手术组并发症发生率为13.3%,显著低于开腹肝切除术组(30.0%,P<0.05);在术后随访6 m,介入手术组总有效率为93.3%,显著高于开腹肝切除术组(80.0%,P<0.05)。结论 采用肝动脉介入栓塞术治疗肝血管瘤患者疗效较好,且可降低血清GPDA、GP73、β2-MG、TNF-α和TSGF水平,明显改善围术期手术相关指标,减少并发症的发生,具有较高的临床安全性。 相似文献
993.
G. Melica A.‐L. Langlois J. Le Goff D. Viglietti D. Glotz J.‐M. Molina M.‐N. Peraldi 《Transplant infectious disease》2014,16(2):344-346
Diarrhea is a frequent complication after kidney transplantation, with an incidence rate between 22% and 51%. In many cases, the cause remains unknown. We describe here the first case, to our knowledge, of persistent diarrhea associated with Coxsackievirus A19 (CVA19) in a kidney transplant recipient. The patient was a 46‐year‐old man who received a deceased‐donor kidney. He experienced delayed graft function because of donor kidney donation after circulatory determination of death. Maintenance immunosuppression consisted of low‐dose cyclosporine, high‐dose mycophenolate mofetil (MMF) (3 g/day), and prednisone (10 mg/day). He had severe diarrhea for 2 weeks associated with acute renal failure. No pathogens were found in the stool cultures. Enterovirus detection was positive by real‐time polymerase chain reaction, and sequence analysis found CVA19 (from Enterovirus C group). Area under the curve of MMF was 48 mg.h/L. Because of the persistence of diarrhea, MMF was stopped and replaced by azathioprine. The diarrhea disappeared, but serum creatinine did not return to baseline. CVA19 rarely causes gastroenteritis. This case illustrates that MMF is not always the direct cause of diarrhea, and that new clinical infectious diseases will be detected with the expansion of molecular‐based DNA diagnostics. 相似文献
994.
995.
Jennifer Jeanne B. Vicera Yenn‐Jiang Lin Po‐Tseng Lee Shih‐Lin Chang Li‐Wei Lo Yu‐Feng Hu Fa‐Po Chung Chin‐Yu Lin Ting‐Yung Chang Ta‐Chuan Tuan Tze‐Fan Chao Jo‐Nan Liao Cheng‐I Wu Chih‐Min Liu Chung‐Hsing Lin Chieh‐Mao Chuang Chun‐Chao Chen Chye Gen Chin Shin‐Huei Liu Wen‐Han Cheng Le Phat Tai Sung‐Hao Huang Ching‐Yao Chou Isaiah Lugtu Ching‐Han Liu Shih‐Ann Chen 《Journal of cardiovascular electrophysiology》2020,31(6):1436-1447
996.
997.
998.
999.
D.A. Dyment E. Sell M.R. Vanstone A.C. Smith D. Garandeau V. Garcia S. Carpentier E. Le Trionnaire F. Sabourdy C.L. Beaulieu J.A. Schwartzentruber H.J. McMillan J. Majewski D.E. Bulman T. Levade K.M. Boycott 《Clinical genetics》2014,86(6):558-563
Spinal muscular atrophy with progressive myoclonic epilepsy (SMA‐PME) is a recently delineated, autosomal recessive condition caused by rare mutations in the N‐acylsphingosine amidohydrolase 1 (acid ceramidase) ASAH1 gene. It is characterized by motor neuron disease followed by progressive myoclonic seizures and eventual death due to respiratory insufficiency. Here we report an adolescent female who presented with atonic and absence seizures and myoclonic jerks and was later diagnosed as having myoclonic‐absence seizures. An extensive genetic and metabolic work‐up was unable to arrive at a molecular diagnosis. Whole exome sequencing (WES) identified two rare, deleterious mutations in the ASAH1 gene: c.850G>T;p.Gly284X and c.456A>C;p.Lys152Asn. These mutations were confirmed by Sanger sequencing in the patient and her parents. Functional studies in cultured fibroblasts showed that acid ceramidase was reduced in both overall amount and enzymatic activity. Ceramide level was doubled in the patient's fibroblasts as compared to control cells. The results of the WES and the functional studies prompted an electromyography (EMG) study that showed evidence of motor neuron disease despite only mild proximal muscle weakness. These findings expand the phenotypic spectrum of SMA‐PME caused by novel mutations in ASAH1 and highlight the clinical utility of WES for rare, intractable forms of epilepsy. 相似文献
1000.